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Letters to the Editor 
Dear Editor 
Mechanisms proposed whereby 
/?-blockers might worsen obstructive 
sleep apnoea (OSA) 
Obstructive sleep apnoea (OSA) is a serious breathing 
disorder characterized by repeated collapse of the upper 
airway during sleep leading to asphyxia and arousal. This 
cycle of throat closure, wakening, a few breaths, snoring 
and throat reblockage can occur hundreds of times in the 
night greatly disturbing the sleep of the sufferer and cause 
excessive daytime sleepiness. 
In a recent paper Fletcher (1) reported that hypertension 
is diagnosed in 90% of OSA patients and OSA can be found 
in 3&35X of patients with diagnosed systemic hyperten- 
sion. P-blockers are often the drug of choice to treat 
hypertension in the general population. 
Longstaff (2) reported the sudden nocturnal death of an 
OSA sufferer after 5 weeks on p-blocker medication, during 
which time the deceased had complained of more sleep 
disruptions and constant fatigue. Increased daytime sleepi- 
ness, memory lapses, morning confusion and apnoea were 
witnessed. Two possible mechanisms (C. W. Zwillich, pers. 
comm., 1997) whereby P-blockade might have worsened 
apnoea were invoked: (a) bradycardia associated with 
apnoea may be worse during b-blockade and could lead to 
cardiac arrest and (b) autonomic excitation which occurs 
during hypercapnia and hypoxaemia may be blunted by /3- 
blockade, resulting in altered arousal responses or extreme 
levels of vasodilation, which is usually counter-balanced by 
some adrenergic stimulation during hypercapnia. 
Vanuxem et al. (3) reported impairment of muscle energy 
metabolism in OSA patients which was linked to repeated 
bouts of nocturnal hypoxaemia. These findings may be 
pertinent to this issue, since any further reduction in energy 
to key muscles, as a result of medication, might possibly 
lead to unwelcome consequences in individuals with 
certain heart problems. D. Vanuxem (pers. comm., 1998) 
has acknowledged that P-blockers might interfere with 
energy metabolism to the striated muscles of the upper 
airways and has proposed the following mechanism: in 
muscle metabolism, the activation of phosphorylase kinase 
by cyclic AMP is triggered by epinephrine and therefore can 
at least be partly impaired by /?-blockade. 
According to Peter et al. (4) cardiac arrest is to be 
expected with severe OSA and p-blockers are not used in 
their sleep laboratory. 
The hypothesis that P-blockers might prolong throat 
closure in OSA sufferers would seem to call for an investi- 
gation, using animal models, into the effect of these drugs 
on upper airway muscle metabolism. 
MARGARET LONGSTAFF 
‘Murrayfield’, Roslin Glen, Rosh, 
Midlofkian EH25 9PX, U.K. 
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Dear Sir 
Re: Ventilation in a Birmingham inten- 
sive care unit 1993-1995: outcome 
for patients with chronic obstructive 
pulmonary disease 
The report by Hill et al. (Respir Med 1998; 92: 156161) 
makes for depressing reading and will reinforce the preju- 
dice in the U.K. against intubation and ventilation in acute 
exacerbations of COPD. In a retrospective study, lack of 
medical documentation should not be taken, necessarily, to 
indicate that treatment options were not discussed with 
patients or relatives. Furthermore, what is the evidence that 
this discussion would limit the demand for ICU admission? 
We advocate discussion about the use of mechanical venti- 
lation with patients between exacerbations but recognize 
the difficulty of neutrality in this, especially in the acute 
situation. 
How many of the patients in Dr Hill’s series were 
admitted from the ward having deteriorated with medical 
therapy? Was admission delayed too long leading to an 
increase in mortality (l)? The value of non-invasive venti- 
lation (NIV) is to avoid the morbidity and mortality of 
intubation (2), yet this was only attempted in two of the 
46 cases. More pertinently, NIV may enable early extuba- 
tion (3). The finding that ICU stay was longer in the 
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survivors than non-survivors is not surprising. For 
instance, in seven cases death followed withdrawal of 
mechanical ventilation. Was early tracheostomy practised? 
This increasingly is recognized to enable earlier discharge 
from the ICU. 
It is difficult to evaluate quality of life in chronic illness. 
Dependency does not equate with reduced quality (4). A 
better evaluation would have been to interview survivors 
and ascertain whether they would opt for mechanical 
ventilation again. Other series (5), involving a much larger 
number of patients, suggest a better outcome than is 
reported here. 
As with previous studies, analysis of prognostic 
indicators demonstrates that there are no sensitive 
measures and that an ‘on the spot’ decision, leaning 
towards provision of mechanical ventilation, is justified. 
NIV should be employed unless contra indications exist. 
If it fails to reverse the spiral towards intubation, it may 
be employed to speed weaning following a short period of 
MV. Surely this is a more appropriate way to care for our 
patients than the nihilistic one suggested by Dr Hill and 
colleagues. 
DR A. C. DAVIDSON* AND 
DR D. F. TREACHERY 
“Consultant Physician, 
Intensive Care and Respiratory Medicine 
‘Director of Intensive Care and Consultant Physician, 
Guy’s and St. Thomas’ Hospital Trust, 
London, U.K. 
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Reply to Drs Davidson and Treacher 
The letter by Davidson and Treacher suggests that the 
paper by Hill et al. (Respir Med 1998; 92: 156161) makes 
for depressing reading and suggests that other series 
show better outcomes. Our series revealed a 49% hospital 
mortality and 59% 1 year mortality: similar outcomes 
were found in U.S. and more recent U.K. studies. In the 
SUPPORT study (1) the 180 day mortality for 348 venti- 
lated patients was 43% (1 year mortality not reported) but 
in another large U.S. study (2), 1 year follow-up was 
available on 167 ventilated COPD patients and in this 
series hospital mortality was 30%, 180 day mortality 48%, 
and 1 year mortality identical to our series at 59%. The 
largest U.K. series by Wildman et al. (3) of 242 ventilated 
COPD patients reports a hospital mortality of 34.2% and 
180 day mortality of 35.5% (1 year mortality data not yet 
reported). We would not agree with the suggestion that 
the article will ‘reinforce the prejudice in the U.K. against 
intubation and ventilation in acute exacerbations of 
COPD’. Davidson and Treacher seem to have missed the 
point of the study which was to stratify a complex case 
mix and identify factors that could prejudice poor out- 
come in 1993 when there was little discussion of this 
important topic in the U.K. 
The low use of NIPPV in our series reflects evidence- 
based practice appropriate to the study period between 
1993 and 1995. At that time the Bott paper (4) had been 
published suggesting the potential for NIPPV within clini- 
cal trials, but did not provide a secure evidence base for its 
wholesale adoption. The subsequent randomized controlled 
trials suggesting a role for NIPPV were not published until 
1995 (5,6) and we agree with the two authors that the ICU 
management of COPD patients will not involve NIPPV, 
with data likely to emerge soon to help decide its role 
outside the ITU. 
Davidson and Treacher question whether admission was 
delayed leading to an increase in mortality and whether 
early tracheostomy was practised in the series by Hill et al. 
The paper did look at whether being admitted to ITU on 
the day of hospital admission influenced outcome. In this 
study there was no difference in outcome whether being 
admitted directly to ITU or following deterioration with 
medical therapy from a medical ward. Tracheostomy was 
and is practised in our intensive care unit if there are 
no signs of ability to wean early and earlier still if 
trachea-bronchial toilet is a problem. 
Davidson and Treacher comment that lack of medical 
documentation should not be taken to indicate that treat- 
ment options were not discussed with patients or relatives, 
and question whether this would influence ICU admission. 
The courts would not necessarily agree with this; what is 
not recorded possibly has not been done-present views 
are not to give professionals the benefit of the doubt where 
medical records are concerned. Discussion can certainly 
influence decision making, for example, one would be more 
likely to ventilate someone with a good pre-morbid history 
without co-morbidities. 
We would restate our contention that the high absolute 
and opportunity costs along with the significant morbidity 
and mortality in this group emphasizes the need for further 
prospective studies to better identify the patients who 
will benefit. We are presently initiating such a study at 
Birmingham Heartlands Hospital and preliminary results 
are expected later in 1999. 
